Advancing Science. Improving Connections.
Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.
Focusing on the unmet medical needs of patients with rare disorders and their families
Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases
Pioneering cannabinoid treatments for neuropsychiatric conditions
Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion SyndromeRead More
Zynerba Pharmaceuticals Provides Update on Recent MilestonesRead More
Zynerba Pharmaceuticals to Present at Two Upcoming Virtual Investor ConferencesRead More
Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational HighlightsRead More